The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.
Stephane Oudard
Honoraria - Bayer; Novartis; Roche; Sanofi
Lisa Sengelov
Honoraria - Sanofi
Paul N. Mainwaring
Consultant or Advisory Role - Consultant
Honoraria - HONORARIA
Antoine Thiery- Vuillemin
Honoraria - Sanofi
Expert Testimony - Sanofi
Christine Theodore
No relevant relationships to disclose
Evgeny Kulikov
No relevant relationships to disclose
Jeffrey Yachnin
Consultant or Advisory Role - Sanofi
Other Remuneration - Other
Ivo Kocak
No relevant relationships to disclose
Vesa V Kataja
Consultant or Advisory Role - advisory board
Marjaana Luukkaa
Consultant or Advisory Role - Janssen Pharmaceutical ; Sanofi
Honoraria - Sanofi
Other Remuneration - Amgen; GlaxoSmithKline; Merck; Roche; Sanofi
Aleander Nosov
No relevant relationships to disclose
Marie Hjelm-Eriksson
No relevant relationships to disclose
Jeffrey Bubis
No relevant relationships to disclose
Liji Shen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Marie-Laure Risse
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
A. Oliver Sartor
Consultant or Advisory Role - Sanofi ; Sanofi
Honoraria - Sanofi ; Sanofi